These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 7237461)

  • 1. Phase II evaluation of cycloleucine in the treatment of patients with disseminated sarcomas.
    Baker LH; Fraile RJ; Samson MK; Cummings G
    Cancer Treat Rep; 1981; 65(3-4):358-9. PubMed ID: 7237461
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of doxorubicin with cycloleucine in the treatment of sarcomas.
    Savlov ED; MacIntyre JM; Knight E; Wolter J
    Cancer Treat Rep; 1981; 65(1-2):21-7. PubMed ID: 7013976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of vindesine sulfate in patients with advanced sarcomas.
    Sordillo PP; Magill GB; Gralla RJ
    Cancer Treat Rep; 1981; 65(5-6):515-6. PubMed ID: 7237472
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of maytansine in advanced sarcomas.
    Edmonson JH; Hahn RG; Creagan ET; O'Connell MJ
    Cancer Treat Rep; 1983 Apr; 67(4):401-2. PubMed ID: 6850657
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of high-dose intermittent cycloleucine in colorectal malignancies.
    Dindogru A; Leichman LP; Cummings G; Baker LH
    Cancer Treat Rep; 1982 Jan; 66(1):203-4. PubMed ID: 7053260
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytostatic activity in vitro of cycloleucine, aspartic acid and glutamic acid phosphonic analogues.
    Duś D; Salwa J; Mastalerz P
    Arch Immunol Ther Exp (Warsz); 1980; 28(3):433-8. PubMed ID: 7447648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
    Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
    Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic suppression of the hyperacute form of experimental allergic encephalomyelitis by tilorone and cycloleucine.
    Levine S; Sowinski R
    Proc Soc Exp Biol Med; 1977 Dec; 156(3):457-60. PubMed ID: 594075
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II trial of anguidine in patients with sarcomas unresponsive to prior chemotherapy: A Southwest Oncology Group Study.
    Thigpen JT; Vaughn C; Stuckey WJ
    Cancer Treat Rep; 1981; 65(9-10):881-2. PubMed ID: 7273022
    [No Abstract]   [Full Text] [Related]  

  • 10. Observations on the human pharmacology of cycloleucine.
    Muggia FM; Loew J; Horwitz S
    Cancer Treat Rep; 1977 Nov; 61(8):1561-3. PubMed ID: 922758
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II study of azotomycin in sarcomas.
    Chang P; Wiernik PH
    Cancer Treat Rep; 1977 Dec; 61(9):1719-20. PubMed ID: 340036
    [No Abstract]   [Full Text] [Related]  

  • 12. Icofungipen (PLIVA).
    Yeates C
    Curr Opin Investig Drugs; 2005 Aug; 6(8):838-44. PubMed ID: 16121691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of diglycoaldehyde in malignant melanomas and soft tissue sarcomas.
    Vosika GJ; Briscoe K; Carey RW; O'Donnell JF; Perry MC; Budman D; Richards F; Coleman M
    Cancer Treat Rep; 1981; 65(9-10):823-5. PubMed ID: 7273013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial.
    Gravis G; Mousseau M; Douillard JY; Dorval T; Fabbro M; Escudier B; Mignot L; Viens P;
    Eur Cytokine Netw; 2001; 12(2):239-43. PubMed ID: 11399511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma.
    Tsuchiya H; Tomita K; Yamamoto N; Mori Y; Asada N
    Anticancer Res; 1998; 18(5B):3651-6. PubMed ID: 9854472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
    Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
    Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
    Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
    Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas.
    Gian VG; Johnson TJ; Marsh RW; Schuhmacher C; Lynch JW
    J Exp Ther Oncol; 1996 May; 1(3):186-90. PubMed ID: 9414403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.